title: Antiamoebic and toxicity studies of a carbamic acid derivative and its therapeutic effect in a hamster model of hepatic amoebiasis.
abstract: Amoebiasis is an important public health problem in developing countries. Entamoeba histolytica, the causative agent of amoebiasis, may develop resistance to nitroimidazoles, a group of drugs considered to be the most effective against this parasitic disease. Therefore, research on new drugs for the treatment of this common infection still constitutes an important therapeutic demand. In the present study we determined the effects of a carbamate derivative, ethyl 4-chlorophenylcarbamate (C4), on trophozoites of E. histolytica strain HM-1:IMSS. C4 was subject to various toxicity tests, including the determination of mutagenicity for bacterial DNA and changes in the enzymatic activities of eukaryotic cells. Genotoxicity studies were performed by the mutagenicity Ames test (plate incorporation and preincubation methods) with Salmonella enterica serovar Typhimurium, with or without metabolic activation produced by the S9 fraction of rat liver. C4 toxicity studies were performed by measuring enzymatic activity in eukaryotic cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan test with Fischer 344 rat hepatocytes. C4 did not induce either frame-shift mutations in S. enterica serovar Typhimurium TA97 or TA98 or base pair substitutions in strains TA100 and TA102. The compound was not toxic for cultured rat hepatic cells. Trophozoites treated with 100 microg of C4 per ml were inhibited 97.88% at 48 h of culture; moreover, damage to the amoebae was also confirmed by electron microscopy. The antiamoebic activity of C4 was evaluated by using an in vivo model of amoebic liver abscess in hamsters. Doses of 75 and 100 mg/100 g of body weight reduced the extent of the amoebic liver abscess by 84 and 94%, respectively. These results justify further studies to clearly validate whether C4 is a new suitable antiamoebic drug.
authors.affiliation: Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN, Apdo. Postal 14-740, México D.F. 07000, México.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Ordaz-Pichardo
authors.forename: Mineko
authors.initials: M
authors.lastname: Shibayama
authors.forename: Saúl
authors.initials: S
authors.lastname: Villa-Treviño
authors.forename: Myriam
authors.initials: M
authors.lastname: Arriaga-Alba
authors.forename: Enrique
authors.initials: E
authors.lastname: Angeles
authors.forename: Mireya
authors.initials: M
authors.lastname: de la Garza
mesh_terms: D000563:Amebicides / Q000627:therapeutic use*; D000818:Animals; D002219:Carbamates / Q000627:therapeutic use* / Q000633:toxicity; D006224:Cricetinae; D004195:Disease Models, Animal; D004748:Entamoeba histolytica; D008099:Liver / Q000503:physiopathology; D008101:Liver Abscess, Amebic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008854:Microscopy, Electron; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000563:Amebicides; D002219:Carbamates
references.citation: J Infect Dis. 1997 Mar;175(3):734-6
references.pmid: 9041357
references.citation: Exp Parasitol. 1998 Jan;88(1):20-7
references.pmid: 9501845
references.citation: Antimicrob Agents Chemother. 1992 Nov;36(11):2392-7
references.pmid: 1283295
references.citation: Antimicrob Agents Chemother. 2001 May;45(5):1505-10
references.pmid: 11302818
references.citation: Arch Invest Med (Mex). 1990;21 Suppl 1:103-7
references.pmid: 2136471
references.citation: Am J Trop Med Hyg. 1997 Jul;57(1):70-4
references.pmid: 9242322
references.citation: Mutat Res. 1983 Apr;117(1-2):79-91
references.pmid: 6339911
references.citation: Trans R Soc Trop Med Hyg. 1978;72(4):431-2
references.pmid: 212851
references.citation: Arch Invest Med (Mex). 1990;21 Suppl 1:23-6
references.pmid: 2136490
references.citation: J Infect Dis. 1989 Feb;159(2):303-9
references.pmid: 2536782
references.citation: Ann Trop Med Parasitol. 1970 Sep;64(3):293-8
references.pmid: 5500101
references.citation: Arch Invest Med (Mex). 1974;5 SUPPL 2:403-10
references.pmid: 4376924
references.citation: Arch Med Res. 1992;23(2):209-12
references.pmid: 1340296
references.citation: Cancer Res. 1979 Aug;39(8):3254-7
references.pmid: 455308
references.citation: Am J Trop Med Hyg. 1998 Dec;59(6):916-21
references.pmid: 9886200
references.citation: Rev Infect Dis. 1983 Nov-Dec;5(6):1093-102
references.pmid: 6140740
references.citation: Surgery. 1983 Jan;93(1 Pt 2):158-64
references.pmid: 6336861
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Arch Invest Med (Mex). 1978;9 Suppl 1:387-92
references.pmid: 29581
references.citation: Mutat Res. 1987 Jun;188(2):111-20
references.pmid: 2884563
references.citation: Rev Infect Dis. 1986 Mar-Apr;8(2):228-38
references.pmid: 2871619
references.citation: Science. 1975 Jun 13;188(4193):1118-9
references.pmid: 766186
references.citation: Arch Invest Med (Mex). 1970;1:Suppl:125-8
references.pmid: 5524339
references.citation: Mutat Res. 1974 Dec;26(6):483-90
references.pmid: 4610373
references.citation: J Antimicrob Chemother. 1980 Sep;6(5):577-93
references.pmid: 6106010
references.citation: Trans R Soc Trop Med Hyg. 1992 Mar-Apr;86(2):170-2
references.pmid: 1440779
references.citation: Toxicol Sci. 2002 Aug;68(2):498-507
references.pmid: 12151647
references.citation: Mutat Res. 1983 May;113(3-4):173-215
references.pmid: 6341825
references.citation: Arch Med Res. 2000 Jul-Aug;31(4 Suppl):S19-20
references.pmid: 11070207